ライフサイエンスコーパス: intrapartum

1 infected in utero than in children infected intrapartum.

2 wo mothers transmitted multiple env variants intrapartum.

3 HIV-1) quasispecies transmitted in utero and intrapartum.

4 other transmitted a single major env variant intrapartum.

5 ransmission occurs late in utero rather than intrapartum.

6 on escape HIV-1 variants occurs in utero and intrapartum.

7 nce in mean scores 0.48 [95% CI 0.41-0.55]), intrapartum (0.28 [0.18-0.37]), hospital-based postnatal

8 had higher mortality than did those infected intrapartum (70% vs. 37% within 2 years), while no signi

9 infections were more likely to have received intrapartum ampicillin than were those with ampicillin-s

10 Stillbirths occurring intrapartum and early in gestation were more common in n

11 he safety, toxicity, and pharmacokinetics of intrapartum and early newborn nevirapine were evaluated

12 antenatally and those that developed in the intrapartum and early post-partum period.

13 rs received a 200-mg single oral dose of NVP intrapartum and infants received either 2-mg/kg oral dos

14 provides HIV-positive women prompt access to intrapartum and neonatal antiretroviral prophylaxis, pro

15 ctronic fetal heart-rate monitoring modifies intrapartum and neonatal outcomes.

16 At 90% coverage, intrapartum and postnatal packages have similar effects

17 HIV-1) transmission occurs during gestation, intrapartum and postpartum (by breast-feeding), 50-70% o

18 d at 28-38 weeks gestation to receive 1 of 3 intrapartum and postpartum regimens: (A) zidovudine plus

19 inistered to the mother during pregnancy and intrapartum and to the infant in the neonatal period has

20 common cause of neonatal mortality--preterm, intrapartum, and infection-related deaths--by 58%, 79%,

21 l practice guidelines for routine antenatal, intrapartum, and postnatal care, categorising them as re

22 nd improve equity and quality for antenatal, intrapartum, and postnatal care, especially in the poore

23 to assess the association between prenatal, intrapartum, and postnatal factors and the development o

24 age and quality of preconception, antenatal, intrapartum, and postnatal interventions by 2025 could a

25 troviral prophylaxis or treatment (prenatal, intrapartum, and postnatal) was 22.4% in 2002-2005 and 3

26 normal physiologic changes during pregnancy, intrapartum, and postpartum is the key to managing criti

27 ciency virus type 1 (HIV-1) occurs in utero, intrapartum, and through breastfeeding, with a cumulativ

28 94 women who were HIV positive, received NVP intrapartum, and were previously antiretroviral treatmen

29 The remaining six intrapartum- and two in utero-infected infants had a hom

30 Intrapartum antibiotic chemoprophylaxis (IAP) prevents m

31 this risk and how it varies with coverage of intrapartum antibiotic prophylaxis (IAP), used to reduce

32 igh-income contexts, despite declines due to intrapartum antibiotic prophylaxis (IAP).

33 f gestation and, if they are colonized, that intrapartum antibiotic prophylaxis be administered.

34 Although intrapartum antibiotic prophylaxis during labor and deli

35 Intrapartum antibiotic prophylaxis is the current mainst

36 Studies that reported use of any intrapartum antibiotic prophylaxis were associated with

37 tion, risk of neonatal disease (with/without intrapartum antibiotic prophylaxis), maternal GBS diseas

38 Despite widespread use of intrapartum antibiotic prophylaxis, group B streptococcu

39 occus (GBS) disease with the introduction of intrapartum antibiotic prophylaxis, this pathogen remain

40 k-based approach) to identify candidates for intrapartum antibiotic prophylaxis.

41 47 (69%) studies reported use of any intrapartum antibiotic prophylaxis.

42 3-2004; the percentage of infants exposed to intrapartum antibiotics increased from 26.8% to 31.7%.

43 Detailed information on delivery method, intrapartum antibiotics, and lifestyle factors was obtai

44 vented by the administration of prophylactic intrapartum antibiotics.

45 tal disease by the wider use of prophylactic intrapartum antibiotics.

46 ng-based approach to identify candidates for intrapartum antibiotics.

47 deaths were prevented in 1998 by the use of intrapartum antibiotics.

48 Increased use of intrapartum antimicrobial prophylaxis in North America a

49 The role of intrapartum asphyxia in neonatal encephalopathy and seiz

50 hildren were defined as infected in utero or intrapartum based on the timing of the first detection o

51 Intrapartum busulfan administration followed by irradiat

52 red out-of-hours had slightly lower rates of intrapartum caesarean section (CS) (12.7% versus 13.4%,

53 We describe configurations of intrapartum care systems, and focus in particular on whe

54 go on to discuss strategies that complement intrapartum care.

55 suggests that implementation of an effective intrapartum-care strategy is an overwhelming priority.

56 reterm labor: aOR, 2.18; 95% CI, 1.06-4.48), intrapartum (cesarean delivery: aOR, 1.77; 95% CI, 1.01,

57 he evolution of the guidelines for selective intrapartum chemoprophylaxis (SIC) of group B streptococ

58 for prevention of perinatal disease through intrapartum chemoprophylaxis were revised in 2002.

59 p B streptococcus to identify candidates for intrapartum chemoprophylaxis.

60 illbirth (odds ratio comparing antepartum or intrapartum complications with no complication 3.96 [95%

61 vidence that GBS is associated with maternal intrapartum complications.

62 three main causes: infections (0.6 million), intrapartum conditions (0.7 million), and preterm birth

63 were reported during the study: one case of intrapartum convulsion and one case of disseminated intr

64 A single intrapartum dose of nevirapine for the prevention of mot

65 The intrapartum dose was missed by 12 women, 4 of whom also

66 to have had intrauterine, 65% (CI, 53%-76%) intrapartum/early postpartum, and 12% (CI, 5%-22%) late

67 The estimated risks for intrauterine, intrapartum/early postpartum, and late postpartum infect

68 transmission risks during the intrauterine, intrapartum/early postpartum, and late postpartum period

69 analysis used as an adjunct to conventional intrapartum electronic fetal heart-rate monitoring did n

70 gment analysis as an adjunct to conventional intrapartum electronic fetal heart-rate monitoring modif

71 Potential mechanisms include prematurity, intrapartum events, or infections.

72 g10 copies per milliliter before therapy and intrapartum exposure to nevirapine were independently as

73 The primary outcome was a composite of intrapartum fetal death, neonatal death, an Apgar score

74 bral palsy and 300 of 378 controls underwent intrapartum fetal monitoring.

75 ation of fetal heart monitoring, advances in intrapartum fetal pulse oximetry, thresholds of acidosis

76 , renal disorders (RRs = 1.54 and 2.56), and intrapartum fever (>100 degrees F) (RRs = 1.17 and 1.69)

77 partum haemorrhage (RR 0.6, 95% CI 0.4-0.9), intrapartum fever (0.4, 0.2-0.9), and use of postpartum

78 IUI was assessed based on intrapartum fever and placenta pathology.

79 luded antepartum or intrapartum haemorrhage, intrapartum fever, postpartum treatment with antibiotics

80 ment group had higher risks of antepartum or intrapartum haemorrhage (RR 0.6, 95% CI 0.4-0.9), intrap

81 ary maternal outcomes included antepartum or intrapartum haemorrhage, intrapartum fever, postpartum t

82 s of PMPA may protect human newborns against intrapartum HIV infection.

83 t mucosal exposure is an important aspect of intrapartum HIV transmission.

84 Antiretroviral regimens can prevent intrapartum HIV transmission; however, these regimens do

85 or to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has l

86 To develop immunoprophylaxis against intrapartum HIV-1 transmission, we used SHIV-vpu+, a chi

87 s the mucosal exposure that can occur during intrapartum HIV-1 transmission.

88 Predictors and prognosis of intrauterine and intrapartum human immunodeficiency virus (HIV) transmiss

89 Single-dose nevirapine reduces intrapartum human immunodeficiency virus 1 type (HIV-1)

90 levant model of perinatal asphyxia providing intrapartum hypoxia in rats.

91 from birth to 24 months in the plasma of 14 intrapartum-infected and 10 uninfected infants born to H

92 Intrapartum intravenous zidovudine (ZDV) prophylaxis is

93 ransmitting in utero (IU) and 9 transmitting intrapartum (IP).

94 The authors examined the relation between intrapartum magnesium sulfate exposure and risk of cereb

95 The continuing incidence of intrapartum morbidity may be partly due to antenatal com

96 Intrapartum MTCT was associated with placental microtran

97 osure therapy in an infant macaque model for intrapartum MTCT.

98 ction model in neonatal macaques that mimics intrapartum mucosal virus exposure.

99 Intrapartum/neonatal nevirapine significantly lowered HI

100 g population in Uganda compared with a short intrapartum/neonatal zidovudine regimen.

101 68 percent of the women who had not received intrapartum nevirapine (P=0.03).

102 e interval, 8%-23%) of 95 women who received intrapartum nevirapine developed a nevirapine-resistance

103 ed when determining the risks or benefits of intrapartum nevirapine in women receiving antepartum ant

104 the third trimester of pregnancy to receive intrapartum nevirapine or placebo.

105 unknown HIV status, which limits the use of intrapartum nevirapine to prevent mother-to-child transm

106 Women who received intrapartum nevirapine were less likely to have virologi

107 in 49 percent of the women who had received intrapartum nevirapine, as compared with 68 percent of t

108 Among the women who had received intrapartum nevirapine, viral suppression was achieved a

109 ions in pregnant women following single-dose intrapartum nevirapine.

110 rom 32 percent of the women who had received intrapartum nevirapine; the most frequent mutations were

111 A 2-dose intrapartum/newborn nevirapine regimen reduced perinatal

112 ssion was low and no benefit from additional intrapartum/newborn nevirapine was demonstrated when wom

113 omatosis (JORRP) is a rare disease caused by intrapartum or perinatal transmission of human papilloma

114 iciency virus (HIV) infection usually occurs intrapartum or postpartum and results in a higher incide

115 o 1) 500 ml or 2) 1000 ml in the antepartum, intrapartum or postpartum period.

116 s appeared to have acquired infection either intrapartum or postpartum.

117 In 2013, most deaths occurred intrapartum or postpartum.

118 olated from a Zambian infant infected either intrapartum or through breastfeeding.

119 tically depending upon the timing (in utero, intrapartum, or during breastfeeding) and potentially th

120 of obstetric complications in the antenatal, intrapartum, or postnatal period, and any neonatal compl

121 the first 2 months of life, either in utero, intrapartum, or through early breast milk transmission,

122 en are due to vertical transmission, and the intrapartum period appears to provide us with a crucial

123 more than 1 million stillbirths occur in the intrapartum period, despite many being preventable.

124 on HIV transmission during pregnancy or the intrapartum period.

125 that transmission usually occurs during the intrapartum period.

126 cterial infection or colonization during the intrapartum period.

127 treatment that can safely be used during the intrapartum period.

128 ment using procedures such as EXIT (ex-utero intrapartum procedure).

129 h life; however, with the advent of ex-utero intrapartum procedure, a few cases of post-natal surviva

130 hreatening or disabling conditions including intrapartum-related brain injury, severe bacterial infec

131 14.9%, 13.0-16.8]; 0.817-1.057 million), and intrapartum-related complications (0.662 million [10.5%,

132 illion, uncertainty range [UR] 0.916-1.325), intrapartum-related complications (9.4%; 0.717 million,

133 neumonia (0.921 million [0.812 -1.117]), and intrapartum-related events (0.691 million [0.598 -0.778]

134 ity rates for pneumonia, diarrhoea, neonatal intrapartum-related events, malaria, and measles were re

135 Intrapartum single-dose (SD) nevirapine (NVP) reduces pe

136 tely 40% of women shortly after they receive intrapartum single-dose nevirapine (SD-NVP).

137 Intrapartum single-dose nevirapine decreases mother-to-c

138 Two women in labor received intrapartum spinal anesthesia from the same anesthesiolo

139 Delivery-related perinatal death, defined as intrapartum stillbirth or neonatal death unrelated to co

140 Most intrapartum stillbirths are associated with obstetric em

141 million (range 0.82 million to 1.97 million) intrapartum stillbirths occur yearly.

142 million (uncertainty range 1.2-1.6 million) intrapartum stillbirths, end preventable maternal and ne

143 Yudkin et al. as the optimum denominator for intrapartum stillbirths, fetuses in utero (or "fetuses a

144 ntribution is even higher for late gestation intrapartum stillbirths.

145 wever, running costs are two-fold higher for intrapartum than for postnatal care.

146 t took place in the hospital after a woman's intrapartum transfer to the hospital.

147 reterm delivery was strongly associated with intrapartum transmission (relative risk, 3.7; 95% confid

148 ered surrogate-nursed kittens suggested that intrapartum transmission may occur.

149 Intrapartum transmission occurred in 24 infants in the z

150 antibodies did not protect infants from the intrapartum transmission of HIV-1.

151 irst week with positive tests later indicate intrapartum transmission.

152 In contrast, intrapartum transmitters were more likely to transmit mi

153 PURPOSE OF REVIEW: The ex-utero intrapartum treatment (EXIT procedure) can be life-savin

154 In this circumstance, the ex-utero intrapartum treatment (EXIT) procedure, which maintains

155 he risk of stillbirth or neonatal death from intrapartum uterine rupture.

156 treatment (EXIT) procedure, which maintains intrapartum uteroplacental support, can be life saving.

157 strategy to prevent postnatal and, possibly, intrapartum virus transmission in a primate model.

158 ection before or during pregnancy (including intrapartum) who deliver liveborn babies at seven sites.

159 mary, MgSO(4) reduced cytokine production in intrapartum women, term and preterm neonates, demonstrat